loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations
IPOLogoImag

SPECIALITY MEDICINES IPO

OPEN

IPO Details

20th Mar 2026
24th Mar 2026
1,000
₹ 1,17,000
₹ 117-124
₹ 29 Crore

Issue timeline

  • 20-24 Mar 2026
  • 25-Mar-2026
  • 27-Mar-2026
  • 27-Mar-2026
  • 30-Mar-2026

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Speciality Medicine Limited operates in the pharmaceutical formulations sector with a focus on high-barrier-to-entry products. The company’s portfolio includes injectables in liquid and lyophilized forms, as well as specialized oral solids. It operates three manufacturing facilities located in Gujarat and Maharashtra, which have received approvals from various global regulatory authorities including the USFDA and EU-GMP. The company’s business model spans across R&D, pilot-scale development, and commercial-scale manufacturing. It distributes its products in domestic markets through a network of stockists and internationally through partnerships in North America, Europe, and emerging markets.

2021
Parth Goyani

Objectives

Setting up of Research and Development (R&D) Centre in Gujarat (₹12.7 crore).
Meet working capital requirements (₹8 crore).
Product registration in International Markets and Product Development for sale in international markets (₹3 crore).
Funding for marketing and promotional activities (₹2 crore).
General corporate purposes.

Strengths & Risks

Strengths (4)

Specialized Manufacturing Infrastructure: Operates facilities capable of handling complex sterile injectables and oncology products with USFDA approvals.

Risks (4)

Regulatory Oversight: Operations are subject to frequent inspections; any failure to comply with Good Manufacturing Practices (GMP) could result in import bans or warnings.

Financials

Industry Overview

  • Global Leadership & Scale: India is the world's largest provider of generic drugs, accounting for 20% of global supply by volume and over 60% of global vaccine demand through a network of 3,000 companies and 10,000 facilities.
  • Strategic Supply Chain Role: With the highest number of USFDA-compliant plants outside the U.S., India is a critical hub for regulated markets including the United States, European Union, and Japan.
  • Specialized Market Shift: The industry is transitioning toward complex generics and sterile injectable, driven by global patent expiries and the need for specialized infrastructure that meets stringent international regulatory filings and quality standards.
Comparison with Listed Industry Peers for FY25 as per RHP
Name of the Company

EPS(₹)

P/E Ratio (x) 

Return on Net Worth (RoNW)

Speciality Medicines Limited
14.1 NA 47.26%
Remus Pharmaceuticals Limited
65.21 10.41 434.25%
Trident Lifeline Limited
10.22 27 56.05%
Mono Pharmacare Limited
1.75 7.49 17.66%

Speciality Medicines IPO FAQs

What is the Speciality Medicines IPO date?

The Speciality Medicines IPO is scheduled to open for public subscription on March 20, 2026, and close on March 24, 2026.

The price band for Speciality Medicines IPO has been fixed in the range of ₹117 to ₹124 per equity share.

The minimum lot size for Speciality Medicines IPO is 1,000 equity shares, requiring an investment of ₹1,17,000 at the upper price band.

The promoters of the company are Parth B Goyani and Goyani Sumit Babubhai.

The shares are proposed to be listed on the BSE and NSE.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.